Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Jun 05, 2023
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK , June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
May 18, 2023
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC models IND enabling studies underway; IND filing on track for 2024 NEW YORK , May 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage
Corporate Presentation

SEC Filings

Form Description Filing date View
DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

 View HTML
0000950123-21-000524.pdf
0000950123-21-000524.rtf
0000950123-21-000524.xls
UPLOAD

UPLOAD

 View HTML
0000000000-21-002119.pdf
0000000000-21-002119.rtf
DRS/A

Amendment to a previously filed DRS

 View HTML
0000950123-21-003599.pdf
0000950123-21-003599.rtf
0000950123-21-003599.xls
UPLOAD

UPLOAD

 View HTML
0000000000-21-003906.pdf
0000000000-21-003906.rtf

Data provided by Kaleidoscope.

Events and Presentations